Scholarlink

<p>Lysine-specific demethylase 1 (LSD1) is an epigenetic regulator implicated in cardiovascular disorders; however, its involvement in atrial fibrillation (AF) remains unclear. This study investigated the role of LSD1 in angiotensin II (Ang II)-induced atrial remodeling and AF susceptibility. Male C57BL/6 mice were infused with Ang II (2.0&#xa0;mg/kg/day) for 28 days to establish an AF-susceptible model. AF inducibility and duration were evaluated using transesophageal burst pacing, and atrial injury and hypertrophy were assessed using biochemical and histological analyses. Ang II infusion significantly increased AF susceptibility and duration, accompanied by atrial hypertrophic remodeling and marked upregulation of LSD1 expression. In vitro, Ang II induced dose-dependent LSD1 expression in HL-1 cardiomyocytes. Silencing LSD1 attenuated Wnt/β-catenin signaling, reduced oxidative stress and inflammatory responses, reduced the expression of hypertrophy-associated markers (ANP and BNP), accompanied by representative morphological changes observed by α-actinin immunofluorescence, and inhibited NLR family pyrin domain-containing 3 (NLRP3) inflammasome activation. Pharmacological activation of Wnt/β-catenin signaling partially reversed these effects. Collectively, these findings identify LSD1 as an upstream epigenetic regulator that promotes Ang II-induced atrial remodeling by independently activating Wnt/β-catenin-dependent hypertrophic signaling and oxidative stress-driven inflammatory pathways, including NLRP3 inflammasome activation, thereby contributing to increased AF susceptibility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

LSD1 is upregulated in angiotensin II-induced atrial remodeling and regulates oxidative stress, inflammatory signaling, and NLRP3 inflammasome activation associated with atrial fibrillation susceptibility

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月24日

查看全文
  • Xinpeng Cong,
  • Jiahui Fang,
  • Zhongping Ning

摘要

Lysine-specific demethylase 1 (LSD1) is an epigenetic regulator implicated in cardiovascular disorders; however, its involvement in atrial fibrillation (AF) remains unclear. This study investigated the role of LSD1 in angiotensin II (Ang II)-induced atrial remodeling and AF susceptibility. Male C57BL/6 mice were infused with Ang II (2.0 mg/kg/day) for 28 days to establish an AF-susceptible model. AF inducibility and duration were evaluated using transesophageal burst pacing, and atrial injury and hypertrophy were assessed using biochemical and histological analyses. Ang II infusion significantly increased AF susceptibility and duration, accompanied by atrial hypertrophic remodeling and marked upregulation of LSD1 expression. In vitro, Ang II induced dose-dependent LSD1 expression in HL-1 cardiomyocytes. Silencing LSD1 attenuated Wnt/β-catenin signaling, reduced oxidative stress and inflammatory responses, reduced the expression of hypertrophy-associated markers (ANP and BNP), accompanied by representative morphological changes observed by α-actinin immunofluorescence, and inhibited NLR family pyrin domain-containing 3 (NLRP3) inflammasome activation. Pharmacological activation of Wnt/β-catenin signaling partially reversed these effects. Collectively, these findings identify LSD1 as an upstream epigenetic regulator that promotes Ang II-induced atrial remodeling by independently activating Wnt/β-catenin-dependent hypertrophic signaling and oxidative stress-driven inflammatory pathways, including NLRP3 inflammasome activation, thereby contributing to increased AF susceptibility.